Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) is expected to release its Q4 2025 earnings data before the market opens on Tuesday, June 10th. Analysts expect Vistagen Therapeutics to post earnings of ($0.53) per share and revenue of $0.18 million for the quarter.
Vistagen Therapeutics Trading Down 0.4%
Vistagen Therapeutics stock traded down $0.01 during trading on Friday, reaching $2.36. The company had a trading volume of 83,745 shares, compared to its average volume of 171,671. Vistagen Therapeutics has a 52 week low of $1.90 and a 52 week high of $4.21. The firm's 50-day simple moving average is $2.29 and its 200 day simple moving average is $2.59. The firm has a market capitalization of $68.11 million, a price-to-earnings ratio of -1.59 and a beta of 0.67.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Vistagen Therapeutics stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,088 shares of the company's stock, valued at approximately $25,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider VistaGen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VistaGen Therapeutics wasn't on the list.
While VistaGen Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
